Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Post-authorization, prospective and unicenter clinical trial, in which patients with UC will
be included. The treatment with anti-TNFα (infliximab, adalimumab or golimumab) or
JAK-inhibitors (tofacitinib) will be initiated by clinical practice and the choice will be
made at the discretion of the investigator at the center where the patients will be recruited
(Hospital Universitario de La Princesa). In the case of the group of patients treated with
tofacitinib, the selection will be made following the action protocol implemented in our
center, in which this drug is usually reserved for those cases refractory to anti-TNFα and/or
vedolizumab. There will be no random assignment of treatment. The drugs will be used in the
approved indications and conditions of use.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa